4//SEC Filing
HARRIS JOHN DAVID 4
Accession 0001209191-17-062897
CIK 0001095981other
Filed
Nov 28, 7:00 PM ET
Accepted
Nov 29, 5:34 PM ET
Size
10.7 KB
Accession
0001209191-17-062897
Insider Transaction Report
Form 4
HARRIS JOHN DAVID
VP and GM Cell Therapy
Transactions
- Exercise of In-Money
Subscription Rights (Right to Buy)
2017-11-28−1→ 0 totalExercise: $1000.00From: 2017-11-02Exp: 2017-11-21→ see footnote - Exercise of In-Money
Warrants (Right to Buy)
2017-11-28+1,800→ 1,800 totalExercise: $0.33Exp: 2020-05-28→ Common Stock (1,800 underlying) - Exercise of In-Money
Series B Preferred Stock
2017-11-28+1→ 1 totalExercise: $0.33From: 2017-11-28→ Common Stock (3,000 underlying)
Footnotes (3)
- [F1]The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.
- [F2]The Series B Preferred Stock has no expiration date.
- [F3]Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020.
Documents
Issuer
CYTORI THERAPEUTICS, INC.
CIK 0001095981
Entity typeother
Related Parties
1- filerCIK 0001655866
Filing Metadata
- Form type
- 4
- Filed
- Nov 28, 7:00 PM ET
- Accepted
- Nov 29, 5:34 PM ET
- Size
- 10.7 KB